Dicerna Pharmaceuticals
Dicerna Pharmaceuticals Inc (Form: DEFA14A, Received: 05/23/2017 16:21:45)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.     )

 

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Pursuant to §240.14a-12

Dicerna Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

     

  (2)  

Aggregate number of securities to which transaction applies:

 

     

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  (4)  

Proposed maximum aggregate value of transaction:

 

     

  (5)  

Total fee paid:

 

     

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount Previously Paid:

 

     

  (2)  

Form, Schedule or Registration Statement No.:

 

     

  (3)  

Filing Party:

 

     

  (4)  

Date Filed:

 

     

 

 

 


*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on July 11, 2017.

 

     

 

Meeting Information

  DICERNA PHARMACEUTICALS, INC.    

 

 Meeting Type:  Annual Meeting

    

 

 

LOGO

 

 

LOGO

 

DICERNA PHARMACEUTICALS, INC.

87 CAMBRIDGEPARK DRIVE

CAMBRIDGE, MA 02140

 

   

 

 For holders as of: May 16, 2017

    
     

 

 Date:  July 11, 2017         Time:  10:00 AM Eastern Time     

     

 

  Location:

 

 

 Dicerna Pharmaceuticals, Inc.

 87 Cambridgepark Drive

 Cambridge, MA 02140

 

    
     

 

You are receiving this communication because you hold shares in the company named above.

 

     

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

 

     

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

     

See the reverse side of this notice to obtain proxy materials and voting instructions.

          
          


  Before You Vote  

How to Access the Proxy Materials

 

   

 

Proxy Materials Available to VIEW or RECEIVE:

          
 

 

NOTICE AND PROXY STATEMENT         FORM 10-K

       
 

 

How to View Online:

       
 

 

Have the information that is printed in the box marked by the arrow LOGO (located on the following page) and visit: www.proxyvote.com.

       
 

 

How to Request and Receive a PAPER or E-MAIL Copy:

       
 

 

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

       
 

1)  BY INTERNET :

  

www.proxyvote.com

       
 

2)  BY TELEPHONE :

  

1-800-579-1639

       
 

3)  BY E-MAIL* :

  

sendmaterial@proxyvote.com

       
 

 

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow LOGO (located on the following page) in the subject line.

       
 

 

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 27, 2017 to facilitate timely delivery.

       
 

 

—  How To Vote  

Please Choose One of the Following Voting Methods

     

 

LOGO         

 

 

 

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow LOGO (located on the following page) available and follow the instructions.

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

       


  Voting Items     
 

 

The Board of Directors recommends you vote FOR

the following proposals:

 

 

1.     Election of Directors

 

        Nominees :

 

1a.  Douglas M. Fambrough, III

 

 

1b.  Martin Freed

 

 

1c.   Brian K. Halak

 

 

1d.  Stephen J. Hoffman

 

 

1e.  Peter Kolchinsky

 

 

1f.    Adam M. Koppel

 

 

1g.  Dennis H. Langer

 

 

1h.  David M. Madden

 

 

1i.    Bruce Peacock

 

LOGO     

 

 

2.    To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017

 

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

 


 

 

 

 

 

LOGO